SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study
- First dose at RadNet, in partnership with Helios Clinical and The Oncology Institute of […]
FAPI-PRO is a GO!
SOFIE is proud to announce FAPI-PRO, our [18F]FAPI-74 Phase 3 study on […]
Another defining moment for SOFIE Biosciences!
Last Friday, November 14, 2025, FAPI-GO, SOFIE’s [18F]FAPI-74 Phase 3 […]
2024 Was a Banner Year for FAPI Tech Transfer!
Thanks to the diligent efforts of our […]
June 9, 2024 (Toronto, CA) – SNMMI annual meeting attendees had the opportunity to learn […]
NEW YORK (June 4, 2024) – Trilantic North America, a growth-focused middle market private equity […]
May 23, 2024 – SOFIE is pleased to partner with Avacta through Avacta’s use […]
June 25, 2023 – For the second year in a row, the spotlight shone on […]